Novel Score to Predict Very Late Recurrences After Catheter Ablation of Atrial Fibrillation.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 02 2021
Historique:
received: 20 09 2020
revised: 31 10 2020
accepted: 03 11 2020
pubmed: 21 11 2020
medline: 16 3 2021
entrez: 20 11 2020
Statut: ppublish

Résumé

Various predictors of atrial fibrillation (AF) recurrence have been shown based on the baseline characteristics before catheter ablation (CA). This study aimed to develop a novel scoring system for predicting very late recurrences of AF (VLRAFs) after an initial CA, taking the postprocedural clinical data into account and reassessing VLRAFs in 12-month patients' condition using previously known preprocedural predictors of AF recurrences. We retrospectively studied 327 patients who underwent an initial CA with freedom from AF for over 12 months. We elucidated the predictors of VLRAFs and created a new score to predict VLRAFs in the discovery AF cohort (n = 181). Thereafter, we investigated whether the new scoring system could accurately predict VLRAFs in the validation AF cohort (n = 146). In the discovery AF cohort, VLRAFs were observed in 53 patients (29%) during the follow-up period (mean follow-up duration: 55 months). The univariate and multivariate Cox proportional-hazards model demonstrated that non-pulmonary vein foci, early recurrences of AF (ERAFs), atrial premature contraction (APC) burden ≥ 142/24 hours, and minimum prematurity index of the APCs ≤ 48% were associated with VLRAFs after CA. We created a new scoring system to predict VLRAFs, the n-PReDCt score (non-pulmonary vein: 1 point, early recurrences of AFs (Recurrences of AF in early phase after CA): 1 point, APC burden ≥ 142/24 hours: 1 point, and minimum prematurity index (= Coupling interval) of the APCs of ≤ 48%: 1 point). The n-PReDCt score was significantly associated with VLRAFs by a Kaplan-Meier analysis in the discovery AF and validation AF cohorts (p < 0.0001 and p < 0.0001, respectively).

Identifiants

pubmed: 33217347
pii: S0002-9149(20)31232-7
doi: 10.1016/j.amjcard.2020.11.008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

49-55

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Yasuyuki Egami (Y)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.

Kohei Ukita (K)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.

Akito Kawamura (A)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.

Hitoshi Nakamura (H)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.

Yutaka Matsuhiro (Y)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.

Koji Yasumoto (K)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.

Masaki Tsuda (M)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.

Naotaka Okamoto (N)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.

Akihiro Tanaka (A)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.

Yasuharu Matsunaga-Lee (Y)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.

Masamichi Yano (M)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.

Ryu Shutta (R)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.

Yasushi Sakata (Y)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Masami Nishino (M)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan. Electronic address: mnishino@osakah.johas.go.jp.

Jun Tanouchi (J)

Department of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH